Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.
Approval Alert | Perioperative Pembrolizumab Plus Radiation in Locally Advanced HNSCC
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel Cancer Vaccine Improves OS vs SOC in Newly Diagnosed GBM
2
ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?
3
FDA Gives Traditional Approval to Pirtobrutinib in CLL/SLL
4
Delving Into the Current State of Clinical Practice in SCLC
5
